If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

If you have metabolic liver disease (MASLD) or its more severe form, MASH, you may be eligible to join a research study testing a new oral drug as a treatment option. This study is evaluating an investigational drug called denifanstat, which may help reduce liver fat and prevent further liver damage. By joining, you'll receive close monitoring of your liver health at no cost, and you could help advance treatment options for others with liver disease. Participation is voluntary, and you'll be able to continue your regular medical care throughout the study. If you're interested in new treatment possibilities and improving your liver health, this could be the right opportunity for you. Speak with our study team today to learn more and see if you qualify!

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Have you ever wondered what environmental toxins you are exposed to on a daily basis, and how it might affect your health? The STRIVE study is looking for volunteers who would like to provide blood, urine, and/or saliva, as well as home samples such as soil, dust, and/or water. In this study, we want to learn more about the environmental factors that contribute to advanced liver disease and liver cancer. We are looking for healthy volunteers and people with liver cirrhosis who live in either North Carolina or Georgia to take part.

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.

Have you been listed for kidney transplant at UNC? If so, you may be able to take part in a research study to help us learn how the process of waiting for a kidney transplant impacts you.

People with kidney disease that have the APOL1 risk variant are at a greater risk for developing protein in their urine and chronic kidney disease. This research study is being done to determine if the investigational drug, VX-147 can slow or stop the worsening of kidney function as well as target the underlying cause of kidney disease.

We still have a lot to learn about why people develop glomerular disease and what the best medicines are to treat these diseases. Diabetes is a common, chronic illness and many people with glomerular disease also have diabetes. Currently, there is no information telling us the best ways to treat patients with both diabetes and glomerular disease, or how to counsel them about prognosis and risks for complications. This substudy of the Cure Glomerulopathy Network brings together information and laboratory specimens from patients with diabetes and glomerular disease to speed up and improve health research for their care.

The CureGN Network acts as a "library" of data for investigators across the world to use to help us ask the following questions: 1) What is the disease?; 2) Why did it happen to me?; 3) Can it be passed down to my family members?; 4) What treatments work the best with the least side effects?